Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of xevinapant in resected squamous cell carcinoma of the head and neck
2022-001144-18Phase 3Active
- Sponsor
- Merck KGaA
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Xevinapant with Placebo (2 arms). Primary endpoint: Disease-Free Survival (DFS). Started Jul 2022; status: active.
02
Drugs
xevinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2022-001144-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001144-18.